Table 1.
Main baseline and clinical outcomes of the study population and comparison with patients not included in the study.
| Main baseline characteristics | All patients (n=169) | Not studied patients (n=118) | p |
|---|---|---|---|
| Recipient age (years) | 52 ± 14 | 52 ± 14 | 0.83 |
| Recipient gender (male) | 110 (65) | 30 (25) | 0.09 |
| Race (Caucasic) | 158 (94) | 113 (96) | 0.41 |
| Cause of end stage disease Vascular Diabetes Glomerular Polycystic kidney disease Interstitial disease Others/unknown |
20 (12) 8 (5) 48 (28) 23 (14) 24 (14) 46 (27) |
21 (18) 14 (12) 30 (25) 16 (14) 11 (9) 26 (22) |
0.12 |
| Time on dialysis (months) | 25 ± 34 | 21 ± 25 | 0.23 |
| Transplant type (deceased) | 115 (68) | 88 (75) | 0.23 |
| Donor age (years) | 55 ± 15 | 54 ± 12 | 0.86 |
| Transplant number (1) | 152 (90) | 106 (90) | 0.98 |
| Cold ischemia time (hours) | 12.8 ± 9.5 | 11 ± 9 | 0.18 |
| Pre-transplant anti-HLA | |||
| (non DSA) antibodies | |||
| Class I | 14 (8) | 10 (8.5) | 0.34 |
| Class II | 17 (10) | 12 (10.2) | 0.30 |
| cPRA (maximum) | 2.8 ± 6.6 | 2.6 ± 5.9 | 0.88 |
| Main immunosuppression | |||
| - Induction | 32 (19)/126 (74)/11 (6) | 30 (25)/85 (72)/3 (2) | 0.14 |
| (rATG/basiliximab/none) | |||
| - Maintenance therapy (CNI, tacrolimus) | 150 (89) | 116 (98) | 0.06 |
| - Steroid withdrawal before 6 months (yes) | 50 (30) | 38 (34) | 0.41 |
| Main clinical outcomes | |||
| DGF | 46 (27) | 36 (31) | 0.54 |
| BPAR TCMR/ABMR |
19 (11) 15/4 |
17 (14) 16/1 |
0.43 0.21/0.33 |
| Patients developing de novo DSA | 24 (14) | 20 | 0.49 |
| HLA class I | 6 | 3 | |
| HLA class II | 19 | 18 | |
| HLA class I and II | 1 | 1 | |
| Death-censored graft loss | 9 (5) | 10 (9) | 0.32 |
| Patient death | 11 (6) | 4 (4) | 0.24 |
Data are mean (standard deviation, SD) or n (%).
cPRA, calculated panel of reactive antibodies; rATG, rabbit anti thymoglobulin; CNI, calcineurin inhibitor; BPAR, biopsy-proven acute rejection; TCMR, T cell mediated rejection; ABMR, antibody-mediated rejection; DSA, donor-specific antibodies.